» Articles » PMID: 15761002

Validity of Composite End Points in Clinical Trials

Citing Articles

Severe maternal morbidity in the high income setting: a systematic review of composite definitions.

Henderson I, Lynch R, Gerry S, McLeish J, Watkinson P, Knight M EClinicalMedicine. 2025; 81:103105.

PMID: 40034571 PMC: 11874727. DOI: 10.1016/j.eclinm.2025.103105.


Update on Clinical Trial Endpoints in Gene Therapy Trials for Inherited Retinal Diseases.

Igoe J, Lam B, Gregori N J Clin Med. 2024; 13(18).

PMID: 39336999 PMC: 11431936. DOI: 10.3390/jcm13185512.


Methodology for the selection and evaluation of outcomes for Chinese herbal injection in acute exacerbation of chronic obstructive pulmonary disease (AECOPD): a comprehensive study.

Kong D, Yang S, Zhao H, Hao X, Zhang T, Lu Y Ann Med. 2024; 56(1):2396567.

PMID: 39253851 PMC: 11389646. DOI: 10.1080/07853890.2024.2396567.


Composite end points and competing risks analysis.

Dayan V, Grant S, Brophy J, Barili F, Freemantle N Interdiscip Cardiovasc Thorac Surg. 2024; 39(1).

PMID: 38954830 PMC: 11262802. DOI: 10.1093/icvts/ivae126.


Composite to Clarity: Shifting From Combined to Individual Endpoints in Meta-Analyses of Cardiovascular Outcome Trials.

Khan S JACC Adv. 2024; 2(7):100548.

PMID: 38939474 PMC: 11198328. DOI: 10.1016/j.jacadv.2023.100548.


References
1.
Dahlof B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):995-1003. DOI: 10.1016/S0140-6736(02)08089-3. View

2.
Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C . Composite outcomes in randomized trials: greater precision but with greater uncertainty?. JAMA. 2003; 289(19):2554-9. DOI: 10.1001/jama.289.19.2554. View

3.
. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348(9038):1329-39. DOI: 10.1016/s0140-6736(96)09457-3. View

4.
. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet. 2001; 358(9286):951-7. DOI: 10.1016/S0140-6736(01)06100-1. View

5.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145-53. DOI: 10.1056/NEJM200001203420301. View